Origin Successfully Achieves Phase IIb GENESIS Trial Objectives Ahead of Schedule and Announces Early Termination of Study PRINCETON, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Origin, Inc., a Phase IIb clinical-stage biotechnology company, today announced that the US Food and Drug Administration has approved its request...

Origin™ Announces Positive Interim Results from Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers Interim results demonstrate strong evidence of healing and favorable safety profileHighest-performing arm (4X per week, 12 minutes):•  95% mean wound-size reduction in 12 weeks•  71% of wounds...

Origin™ Announces First 50 Patients Randomized, and Full Site Activation in Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers PRINCETON, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Origin, Inc. (formerly Advanced Plasma Therapies, Inc), a Princeton, NJ based clinical-stage wound care company focused on treatment of Diabetic...